Quince Therapeutics (QNCX) Competitors $1.24 -0.02 (-1.59%) Closing price 04:00 PM EasternExtended Trading$1.24 0.00 (-0.40%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock QNCX vs. NVCT, ENGN, ITOS, MNPR, SOPH, DSGN, HUMA, ANNX, CRDF, and INMBShould you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Nuvectis Pharma (NVCT), enGene (ENGN), iTeos Therapeutics (ITOS), Monopar Therapeutics (MNPR), SOPHiA GENETICS (SOPH), Design Therapeutics (DSGN), Humacyte (HUMA), Annexon (ANNX), Cardiff Oncology (CRDF), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry. Quince Therapeutics vs. Nuvectis Pharma enGene iTeos Therapeutics Monopar Therapeutics SOPHiA GENETICS Design Therapeutics Humacyte Annexon Cardiff Oncology INmune Bio Quince Therapeutics (NASDAQ:QNCX) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Which has preferable earnings & valuation, QNCX or NVCT? Nuvectis Pharma is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuince TherapeuticsN/AN/A-$31.39M-$1.31-0.95Nuvectis PharmaN/AN/A-$22.26M-$1.11-7.43 Is QNCX or NVCT more profitable? Quince Therapeutics' return on equity of -53.27% beat Nuvectis Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Quince TherapeuticsN/A -53.27% -22.73% Nuvectis Pharma N/A -155.80%-104.02% Do analysts prefer QNCX or NVCT? Quince Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 545.16%. Nuvectis Pharma has a consensus price target of $15.67, suggesting a potential upside of 89.90%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Quince Therapeutics is more favorable than Nuvectis Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Nuvectis Pharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in QNCX or NVCT? 30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 16.8% of Quince Therapeutics shares are held by insiders. Comparatively, 35.8% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, QNCX or NVCT? Quince Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. Does the media prefer QNCX or NVCT? In the previous week, Nuvectis Pharma had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 4 mentions for Nuvectis Pharma and 3 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.64 beat Nuvectis Pharma's score of 0.25 indicating that Quince Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quince Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in QNCX or NVCT? Nuvectis Pharma received 3 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 92.31% of users gave Nuvectis Pharma an outperform vote. CompanyUnderperformOutperformQuince TherapeuticsOutperform Votes9100.00% Underperform VotesNo VotesNuvectis PharmaOutperform Votes1292.31% Underperform Votes17.69% SummaryQuince Therapeutics beats Nuvectis Pharma on 10 of the 16 factors compared between the two stocks. Remove Ads Get Quince Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNCX vs. The Competition Export to ExcelMetricQuince TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.56M$2.83B$5.24B$7.07BDividend YieldN/A1.53%4.87%4.05%P/E Ratio-1.0029.1621.1817.48Price / SalesN/A420.20356.3585.27Price / CashN/A168.6838.1634.64Price / Book0.633.486.233.79Net Income-$31.39M-$72.06M$3.20B$247.10M7 Day Performance-8.15%-12.92%-8.32%-7.32%1 Month Performance-15.65%-20.23%-3.36%-10.19%1 Year Performance19.23%-34.36%2.72%-7.41% Quince Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNCXQuince Therapeutics2.2365 of 5 stars$1.24-1.6%$8.00+545.2%+20.0%$54.56MN/A-1.0060Upcoming EarningsNVCTNuvectis Pharma2.3097 of 5 stars$9.77-6.6%$15.00+53.5%+9.7%$228.54MN/A-8.428Analyst ForecastNews CoverageENGNenGene2.9172 of 5 stars$4.48+4.2%$25.22+463.0%-72.8%$228.38MN/A-7.7231ITOSiTeos Therapeutics2.5357 of 5 stars$5.97-5.5%$25.75+331.3%-56.6%$228.02M$35M-1.9090Gap DownMNPRMonopar Therapeutics2.2402 of 5 stars$36.41-9.7%$44.00+20.8%+977.6%$222.17MN/A-18.4810Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews CoverageSOPHSOPHiA GENETICS2.7603 of 5 stars$3.32+1.8%$6.80+104.8%-41.7%$221.40M$65.17M-3.05520Positive NewsDSGNDesign Therapeutics1.2044 of 5 stars$3.86-8.3%$8.00+107.3%-4.9%$219.11MN/A-4.5440Positive NewsGap DownHUMAHumacyte2.0037 of 5 stars$1.71-12.8%$13.71+702.0%-52.1%$215.22M$1.57M-1.28150Earnings ReportGap DownHigh Trading VolumeANNXAnnexon1.8526 of 5 stars$1.93-14.2%$17.25+793.8%-71.6%$211.74MN/A-1.8460Gap DownHigh Trading VolumeCRDFCardiff Oncology0.9056 of 5 stars$3.14-4.6%$11.67+271.5%-46.2%$208.89M$683,000.00-3.3420News CoverageGap DownINMBINmune Bio1.528 of 5 stars$7.81+3.9%$22.80+191.9%-23.1%$207.68M$42,000.00-3.5810 Remove Ads Related Companies and Tools Related Companies Nuvectis Pharma Alternatives enGene Alternatives iTeos Therapeutics Alternatives Monopar Therapeutics Alternatives SOPHiA GENETICS Alternatives Design Therapeutics Alternatives Humacyte Alternatives Annexon Alternatives Cardiff Oncology Alternatives INmune Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QNCX) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
